Investigational COVID-19 vaccine well-tolerated, generates immune response in older adults

A Phase 1 trial of an investigational mRNA vaccine to prevent SARS-CoV-2 infection has shown that the vaccine is well-tolerated and generates a strong immune response in older adults. A report published today in the New England Journal of Medicine describes the findings from the study, which was supported by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health.
Source: World Pharma News - Category: Pharmaceuticals Tags: Featured EMA Regulatory Affairs Source Type: news

Related Links:

AbstractObjectives: The Bacille Calmette-Gu érin (BCG) vaccine against tuberculosis is associated with non- specific protective effects against other infections, and significant reductions in all-cause morbidity and mortality have been reported. We aim to test whether BCG vaccination may reduce susceptibility to and/or the severity of COVID- 19 and other infectious diseases in health care workers (HCW) and thus prevent work absenteeism.The primary objective is to reduce absenteeism due to illness among HCW during the COVID-19 pandemic. The secondary objectives are to reduce the number of HCW that are infected with S...
Source: Trials - Category: Research Source Type: clinical trials
ConclusionThe MESV developed in this study is capable of generating immune response against COVID-19. Therefore, if designed MESV further investigated experimentally, it would be an effective vaccine candidate against SARS-CoV-2 to control and prevent COVID-19.
Source: Infectious Diseases of Poverty - Category: Infectious Diseases Source Type: research
The cleverest of enemies thrive on surprise attacks. Viruses—and coronaviruses in particular—know this well. Remaining hidden in animal hosts for decades, they mutate steadily, sometimes serendipitously morphing into more effective and efficient infectious agents. When a strain with just the right combination of genetic codes that spell trouble for people makes the leap from animal to human, the ambush begins. Such was the case with SARS-CoV-2, the coronavirus behind COVID-19, and the attack was mostly silent and insidious at first. Many people infected with SARS-CoV-2 remained oblivious as they served as the v...
Source: TIME: Health - Category: Consumer Health News Authors: Tags: Uncategorized COVID-19 Magazine Source Type: news
The last time most of us gave any thought to antibodies was probably in high school biology, but we’re getting a crash refresher course thanks to COVID-19. They are, after all, the key to our best defenses against SARS-CoV-2, the virus that’s caused the global pandemic. People who have been infected likely rely on antibodies to recover, and antibodies are what vaccines are designed to produce. Or at least that’s what infectious-disease and public-health experts assume for now. Because SARS-CoV-2 is such a new virus, even the world’s best authorities aren’t yet sure what it will take to build p...
Source: TIME: Health - Category: Consumer Health News Authors: Tags: Uncategorized COVID-19 Source Type: news
This report updates the 2019-20 recommendations of the Advisory Committee on Immunization Practices (ACIP) regarding the use of seasonal influenza vaccines in the United States (MMWR Recomm Rep 2019;68[No. RR-3]). Routine annual influenza vaccination is recommended for all persons aged ≥6 months who do not have contraindications. For each recipient, a licensed and age-appropriate vaccine should be used. Inactivated influenza vaccines (IIVs), recombinant influenza vaccine (RIV4), and live attenuated influenza vaccine (LAIV4) are expected to be available. Most influenza vaccines available for the 2020-21 season will be qu...
Source: MMWR Recomm Rep - Category: Epidemiology Authors: Tags: MMWR Recomm Rep Source Type: research
By Folake OlayinkaAug 15 2020 (IPS) In 1918, the Spanish Flu, a deadly influenza caused by the H1N1 virus, decimated the world. Over the course of four successive waves, it infected 500 million people, about a third of the world’s population at the time, resulting in 50 million deaths. More recently between 2014 and mid-2016 , the Ebola virus epidemic was the most widespread outbreak of Ebola virus disease in history—causing devastating  loss of life and socioeconomic disruption in the West Africa region, mainly in Guinea, Liberia and Sierra Leone. These outbreaks, as well as SARS and MERS, each have ...
Source: IPS Inter Press Service - Health - Category: International Medicine & Public Health Authors: Tags: Democracy Headlines Health Source Type: news
It is a frightening time to live in the United States. COVID-19, a novel disease as ruthless as it is seemingly random, is picking us off by the thousands; even many of those who “recover” may never truly be the same again. The pandemic has exposed the gulf between what this country promises for its citizens and what it actually delivers. And as the U.S. barrels toward Election Day, the outbreak is sure to complicate the voting process, with potentially disastrous results. For a short time in the spring, it appeared the U.S. was getting a grip on its outbreak. Hard-hit states like New York successfully flattene...
Source: TIME: Science - Category: Science Authors: Tags: Uncategorized COVID-19 UnitedWeRise20Disaster Source Type: news
CONCLUSION: In light of these unprecedented times, the need to understand the nuances of these viral respiratory pathogens, especially SARS-CoV-2, cannot be overemphasized. This knowledge base is of particular importance to otolaryngologists, whose expertise in the upper airway coincides with the anatomic tropism of these infectious agents. PMID: 32762250 [PubMed - as supplied by publisher]
Source: American Journal of Rhinology and Allergy - Category: ENT & OMF Authors: Tags: Am J Rhinol Allergy Source Type: research
Two doses of an experimental vaccine to prevent coronavirus disease 2019 (COVID-19) induced robust immune responses and rapidly controlled the coronavirus in the upper and lower airways of rhesus macaques exposed to SARS-CoV-2, report scientists from the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health. SARS-CoV-2 is the virus that causes COVID-19.
Source: World Pharma News - Category: Pharmaceuticals Tags: Featured Research Research and Development Source Type: news
Moderna Therapeutics and the National Institute of Allergy and Infectious Diseases (NIAID) announced today that researchers had injected the first volunteer in the first U.S. coronavirus vaccine to reach the final, phase 3 stage of testing. That person received the shot at 6:45 am eastern time in Savannah, Geo., Dr. Anthony Fauci, director of the National Institute of Allergy and Infectious Diseases of the National Institutes of Health (NIH) told reporters during a briefing. Because the trial will randomly assign participants to receive either the vaccine or a placebo, and neither the researchers nor the volunteers will kn...
Source: TIME: Health - Category: Consumer Health News Authors: Tags: Uncategorized COVID-19 Source Type: news
More News: Allergy | Allergy & Immunology | COVID-19 | Infectious Diseases | National Institutes of Health (NIH) | Pharmaceuticals | SARS | Study | Vaccines